Stay updated on KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer

Sign up to get notified when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.
Latest website image capture
Clouds background image

Latest updates to the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page

  1. Check
    7 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-17T22:28:01.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov release label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:20:32.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    35 days ago
    Change Detected
    Summary
    The content now presents a 403 Forbidden error page, replacing the study details with a standard error view. The header and surrounding footer indicate a blocked access state rather than the searchable study information.
    Difference
    19%
    Check dated 2026-09-19T21:01:31.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    - The study record now shows Revision: v3.6.6, replacing the prior v3.6.5. This appears to be a metadata version update rather than a substantive change to study data or eligibility information.
    Difference
    0.1%
    Check dated 2026-08-29T19:58:42.000Z thumbnail image
  6. Check
    77 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.5, replacing Revision: v3.6.4. This appears to be a routine site version update affecting only the underlying code/version label, not the study details.
    Difference
    0.1%
    Check dated 2026-08-08T22:32:40.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    New PubMed-listed publication citation was added to the Publications section (Cancer Res Commun. 2026) for the study. A PubMed auto-fill note with revision 3.6.4 was also included, clarifying the source of automatically pulled text.
    Difference
    0.2%
    Check dated 2026-07-25T13:13:00.000Z thumbnail image

Stay in the know with updates to KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer

Enter your email address, and we'll notify you when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.